{
    "root": "5acefb4c-d817-4aa3-890a-1eafe1f4ec7f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "CYCLOPHOSPHAMIDE",
    "value": "20250130",
    "ingredients": [
        {
            "name": "CYCLOPHOSPHAMIDE",
            "code": "8N3DW7272P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4027"
        }
    ],
    "indications": {
        "text": "cyclophosphamide injection alkylating indicated treatment adults pediatric patients : \u2022 malignant diseases : malignant lymphomas : hodgkin \u2019 disease , lymphocytic lymphoma , mixed-cell type lymphoma , histiocytic lymphoma , burkitt \u2019 lymphoma ; multiple myeloma , leukemias , mycosis fungoides , neuroblastoma , adenocarcinoma ovary , retinoblastoma , breast carcinoma ( 1.1 ) \u2022 minimal change nephrotic syndrome pediatric patients : biopsy proven minimal change nephrotic syndrome patients failed adequately respond unable tolerate adrenocorticosteroid therapy ( 1.2 ) limitations : safety effectiveness treatment nephrotic syndrome adults renal disease established . ( 1.2 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "lymphoma (DOID:0060058)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060058"
            },
            {
                "text": "histiocytic lymphoma (DOID:8538)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8538"
            },
            {
                "text": "multiple myeloma (DOID:9538)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9538"
            },
            {
                "text": "mycosis (DOID:1564)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1564"
            },
            {
                "text": "mycosis fungoides (DOID:8691)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8691"
            },
            {
                "text": "neuroblastoma (DOID:769)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_769"
            },
            {
                "text": "adenocarcinoma (DOID:299)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_299"
            },
            {
                "text": "retinoblastoma (DOID:768)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_768"
            },
            {
                "text": "breast carcinoma (DOID:3459)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3459"
            },
            {
                "text": "carcinoma (DOID:305)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_305"
            },
            {
                "text": "nephrotic syndrome (DOID:1184)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1184"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "immediately cyclophosphamide injection , administer adequate amounts fluid reduce risk urinary tract toxicity ( 2.1 ) . malignant diseases : adult pediatric patients ( 2.2 ) \u2022 intravenous : initial course patients hematologic deficiency : 40 mg per kg 50 mg per kg divided doses 2 5 days . regimens include 10 mg per kg 15 mg per kg given every 7 10 days 3 mg per kg 5 mg per kg twice weekly . \u2022 oral : 1 mg per kg per day 5 mg per kg per day initial maintenance dosing . minimal change nephrotic syndrome pediatric patients ( 2.3 ) \u2022 oral : 2 mg per kg daily 8 12 weeks ( maximum cumulative dose 168 mg per kg ) . \u2022 treatment beyond 90 days increases probability sterility males . ( 8.4 )",
        "doid_entities": [
            {
                "text": "nephrotic syndrome (DOID:1184)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1184"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "cyclophosphamide injection , usp sterile white powder containing cyclophosphamide supplied single-dose vials . cyclophosphamide injection , usp ndc 10019-938-01 500 mg/vial , carton 1 ndc 10019-939-01 1 g/vial , carton 1 ndc 10019-942-01 2 g/vial , carton 1 store vials 25\u00b0c ( 77\u00b0f ) . transport storage cyclophosphamide vials , temperature influences lead melting active ingredient , cyclophosphamide [ ( 2.4 ) ] . cyclophosphamide hazardous product . follow special handling disposal procedures.1",
    "adverseReactions": "hypersensitivity cyclophosphamide injection contraindicated patients history severe hypersensitivity cyclophosphamide , metabolites , components product . anaphylactic including death reported cyclophosphamide . cross-sensitivity alkylating agents occur . urinary outflow obstruction cyclophosphamide injection contraindicated patients urinary outflow obstruction [ ( 5.2 ) ] .",
    "indications_original": "Cyclophosphamide for Injection is an alkylating drug indicated for treatment of adults and pediatric patients with: \u2022 Malignant Diseases : malignant lymphomas: Hodgkin\u2019s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt\u2019s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) \u2022 Minimal Change Nephrotic Syndrome in Pediatric Patients : biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 ) Limitations of Use: The safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established. ( 1.2 )",
    "contraindications_original": "During or immediately after Cyclophosphamide for Injection administration, administer adequate amounts of fluid to reduce the risk of urinary tract toxicity ( 2.1 ). Malignant Diseases: Adult and Pediatric Patients ( 2.2 ) \u2022 Intravenous: Initial course for patients with no hematologic deficiency: 40 mg per kg to 50 mg per kg in divided doses over 2 to 5 days.  Other regimens include 10 mg per kg to 15 mg per kg given every 7 to 10 days or 3 mg per kg to 5 mg per kg twice weekly. \u2022 Oral: 1 mg per kg per day to 5 mg per kg per day for both initial and maintenance dosing. Minimal Change Nephrotic Syndrome in Pediatric Patients ( 2.3 ) \u2022 Oral: 2 mg per kg daily for 8 to 12 weeks (maximum cumulative dose 168 mg per kg). \u2022 Treatment beyond 90 days increases the probability of sterility in males. ( 8.4 )",
    "warningsAndPrecautions_original": "Cyclophosphamide for Injection, USP is a sterile white powder containing cyclophosphamide and is supplied in single-dose vials.\n                  Cyclophosphamide for Injection, USP\n                  \n                     \n                        \u00a0NDC 10019-938-01\t500 mg/vial, carton of 1\n                     \n                        \u00a0NDC 10019-939-01\t1 g/vial, carton of 1\n                     \n                        \u00a0NDC 10019-942-01\t2 g/vial, carton of 1\n                  \n                  Store vials at or below 25\u00b0C (77\u00b0F). During transport or storage of cyclophosphamide vials, temperature influences can lead to melting of the active ingredient, cyclophosphamide [see \n                     \n                        Dosage and Administration (2.4)\n                     \n                     ]. \n                  Cyclophosphamide is a hazardous product.  Follow special handling and disposal procedures.1",
    "adverseReactions_original": "Hypersensitivity\n                     \n                     \n                        \u00a0Cyclophosphamide for Injection for contraindicated in patients who have a history of severe hypersensitivity reactions to cyclophosphamide, any of its metabolites, or to other components of the product. Anaphylactic reactions including death have been reported with cyclophosphamide. Cross-sensitivity with other alkylating agents can occur.\n                     \n                        \u00a0\n                        Urinary Outflow Obstruction\n                     \n                     \n                        \u00a0Cyclophosphamide for Injection is contraindicated in patients with urinary outflow obstruction [see Warnings and Precautions (5.2)].",
    "drug": [
        {
            "name": "CYCLOPHOSPHAMIDE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4027"
        }
    ]
}